Abstract
<h3>Objective.</h3> —To evaluate the fiscal impact and the cost-effectiveness of monoclonal antibodies against gram-negative endotoxin (MAbGNE) in the treatment of presumed gram-negative sepsis. <h3>Design.</h3> —A decision analysis model was developed from (1) data from two phase III trials that studied the E5 or HA-1A MAbGNE, and (2) financial data from 1405 septic patients who required intensive care at a large tertiary hospital. <h3>Setting.</h3> —Intensive care unit (ICU) patients with presumed gram-negative sepsis. <h3>Patients.</h3> —The E5 trial evaluated 468 patients, and the HA-1A study enrolled 543 patients with presumed gram-negative sepsis. <h3>Interventions.</h3> —The addition of MAbGNE to standard regimens or standard regimens alone. <h3>Main Outcome Measures.</h3> —Total expected charges and the expected probability of survival were determined for each option. Cost-effectiveness and marginal cost-effectiveness ratios were also derived. Multiple sensitivity and Monte Carlo analyses were performed to test the underlying assumptions. <h3>Results.</h3> —MAbGNE therapy always resulted in higher expected charges; however, these differences were less than its acquisition cost by $870. The cost-effectiveness ratio for MAbGNE, for $2000 and $4000 acquisition costs, was $71 674 and $74 900 per probability of survival, respectively. Sensitivity analysis showed that cost-effectiveness was most affected by diagnostic accuracy, patient selection, and acquisition cost. Monte Carlo analysis showed that MAbGNE was more costly for 71% of simulations, yet the most efficacious option for 79% of simulations. <h3>Conclusions.</h3> —From the perspective of acute care institutions, MAbGNE is expensive and cannot be justified on a cost-saving basis. However, it may be cost-effective throughout a reasonable range of assumptions. (<i>JAMA</i>. 1993;269:249-254)
Keywords
MedicineGramSepsisMonoclonal antibodyGram-negative bacteriaIntensive care medicineGram-negative bacterial infectionsAntibodyImmunologyMicrobiologyAntibioticsBacteriaEscherichia coli
Affiliated Institutions
Related Publications
APACHE II
This paper presents the form and validation results of APACHE II, a severity of disease classification system. APACHE II uses a point score based upon initial values of 12 routi...
Severe sepsis epidemiology: sampling, selection, and society.
Three new articles in Critical Care add to an expanding body of information on the epidemiology of severe sepsis. Although there have been a range of approaches to estimate the ...
The Epidemiology of Sepsis in the United States from 1979 through 2000
The incidence of sepsis and the number of sepsis-related deaths are increasing, although the overall mortality rate among patients with sepsis is declining. There are also dispa...
Surviving Sepsis Campaign
To provide an update to the "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," last published in 2008. A consensus committee of 68 internat...
Publication Info
- Year
- 1993
- Type
- article
- Volume
- 269
- Issue
- 2
- Pages
- 249-249
- Citations
- 102
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
102
OpenAlex
Cite This
Donald B. Chalfin
(1993).
Cost-effectiveness of Monoclonal Antibodies to Gram-negative Endotoxin in the Treatment of Gram-negative Sepsis in ICU Patients.
JAMA
, 269
(2)
, 249-249.
https://doi.org/10.1001/jama.1993.03500020083037
Identifiers
- DOI
- 10.1001/jama.1993.03500020083037